NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus Pharma TM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic...
Eric So, Interim CEO, to participate in a fireside chat on Thursday, June 4 at 2:35 p.m. EDT NEW YORK and TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP),...
NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans...
Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP)...
Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments...
Addition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK and TORONTO, April 23, 2026...
NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic...
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17,...
Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and...
Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industry Appointment supports Helus Pharma’s continued maturation as the company...